What is the current Price Target for the Unity Biotechnology, Inc. stock?

The average Unity Biotechnology, Inc. target price is $6.67. This is 460.22% higher than the current stock price. The highest price target is 572.27%, the lowest is 404.20%. 3 Analysts have issued a price target Unity Biotechnology, Inc. 2025 .

How high will the Unity Biotechnology, Inc. stock rise?

No reliable answer can be given as to how high the Unity Biotechnology, Inc. stock will rise. The performance of stocks, including the Unity Biotechnology, Inc. stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Unity Biotechnology, Inc. stock today?

The performance of Unity Biotechnology, Inc. stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Unity Biotechnology, Inc. stock fall?

The decline in Unity Biotechnology, Inc. stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Unity Biotechnology, Inc. Forecast, price target & analysts

$1.19

4.39% yesterday

Nasdaq, Nov 25, 10:00 pm CET

ISIN

US91381U1016

Symbol

UBX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Unity Biotechnology, Inc. Target price 2024 - Analyst rating & recommendation

Unity Biotechnology, Inc. Classifications & Recommendation:

Buy

100%

Unity Biotechnology, Inc. Price Target

Target Price	$6.67
Price	$1.19
Potential	460.22% register free of charge
Number of Estimates	3

	3 Analysts have issued a price target Unity Biotechnology, Inc. 2025 . The average Unity Biotechnology, Inc. target price is $6.67. This is 460.22% register free of charge higher than the current stock price. The highest price target is $8.00 572.27% register free of charge , the lowest is $6.00 404.20% register free of charge .
	A rating was issued by 3 analysts: 3 Analysts recommend Unity Biotechnology, Inc. to buy, 0 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Unity Biotechnology, Inc. stock has an average upside potential 2025 of 460.22% register free of charge . Most analysts recommend the Unity Biotechnology, Inc. stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Annually

	Dec '23	2024 Estimates
Earnings Per Share $	-2.70	-1.50
	57.21%	44.44%
P/E		negative

The average Unity Biotechnology, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2023.

This results in the following potential growth metrics and future valuations:

2023	$-2.70	57.21%
2024	$-1.50 44.44% Unlock
2025	$-1.50 0.00% Unlock

Current	-0.90	55.17%
2024	-0.79 12.22% Unlock
2025	-0.79 0.00% Unlock

Unity Biotechnology, Inc....

Discover more stocks with a high price target

Valneva 284.61%

CureVac N.V. 145.33%

Moderna 70.75%

Bavarian Nordic 61.25%

Nel ASA 44.32%

Aixtron 43.84%

Volkswagen VZ 41.85%

Alibaba Group Holding Ltd 40.45%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now